Xellia Pharms Aps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?
XELLIA PHARMS APS has sixteen approved drugs.
There are seven US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.
Summary for Xellia Pharms Aps
| International Patents: | 50 |
| US Patents: | 7 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 16 |
Drugs and US Patents for Xellia Pharms Aps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 211713-001 | Jun 2, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-003 | Feb 15, 2019 | RX | Yes | Yes | 10,188,697 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-004 | Feb 15, 2019 | RX | Yes | Yes | 10,188,697 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Xellia Pharms Aps Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 3215173 | ⤷ Try a Trial |
| Japan | 6797795 | ⤷ Try a Trial |
| Poland | 3542812 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Xellia Pharms Aps Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1115417 | CA 2006 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCIN |
| 0536515 | C300244 | Netherlands | ⤷ Try a Trial | PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424 |
| 0620232 | 44/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
